Natera
NTRA
$332.03
+2.21%
Natera, Inc. is a diagnostic and research company that leverages proprietary molecular and bioinformatics technology to develop and commercialize advanced genetic testing products, primarily in the areas of prenatal screening, carrier screening, oncology (molecular residual disease), and organ transplant monitoring. The company is a market leader in non-invasive prenatal testing (NIPT) with its Panorama test and has established a strong presence in the emerging liquid biopsy space with its Signatera MRD test, positioning it as a key player in precision medicine. The current investor narrative centers on the company's rapid revenue growth, driven by the adoption of Signatera and its expansion into new indications, as well as its recent achievement of GAAP profitability in Q4 2025, which has fueled optimism about its path to sustained profitability and market share gains in the diagnostics industry.…
NTRA
Natera
$332.03
Related headlines
Investment Opinion: Should I buy NTRA Today?
Based on the strong growth trajectory, recent profitability milestone, and analyst consensus of Strong Buy, I rate NTRA a Buy, but with a caveat that the valuation is stretched. The average analyst target of $336.74 offers only 1.4% upside, but the high target of $375 implies 12.9% upside, and the low target of $280 implies -15.7% downside. The thesis is supported by 38.8% YoY revenue growth, improving gross margins (64.8%), and a leadership position in the MRD market. However, the PS ratio of 13.58x is far above the industry average of 2.5x, and the negative EPS means the stock is priced for perfection. This Buy would be downgraded to Hold if revenue growth decelerates below 30% or if the PS ratio compresses below 10x, and upgraded to a stronger Buy if the company delivers consistent GAAP profitability and maintains growth above 40%. Overall, the stock is overvalued relative to its history and peers, but the growth potential justifies a premium for investors with a high risk tolerance.
Sign up to view all
NTRA 12-Month Price Forecast
The AI assessment is bullish on NTRA's growth prospects, but with medium confidence due to the extreme valuation and inconsistent profitability. The company's leadership in MRD testing and accelerating revenue growth are strong positives, but the stock is priced for perfection, and any misstep could lead to a sharp correction. I would upgrade to high confidence if the company delivers two consecutive quarters of GAAP profitability and maintains growth above 35%, and downgrade to neutral if growth falls below 25% or if the PS ratio compresses below 10x.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Natera's 12-month outlook, with a consensus price target around $336.74 and implied upside of +1.4% versus the current price.
Average Target
$336.74
0 analysts
Implied Upside
+1.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$280 - $375
Analyst target range
The target price range spans from $280.00 (low) to $375.00 (high), reflecting a wide spread of 34% between the low and high estimates. The high target of $375 assumes continued strong growth in Signatera and successful expansion into new markets, while the low target of $280 suggests concerns about competitive pressures or slower-than-expected adoption. Recent ratings actions have been mostly positive, with firms like Canaccord Genuity and Morgan Stanley reiterating Buy/Overweight ratings, though Goldman Sachs downgraded from Buy to Neutral in June 2026. The wide range indicates significant uncertainty about the company's future performance, but the overall positive sentiment suggests analysts are optimistic about Natera's long-term prospects.
Bulls vs Bears: NTRA Investment Factors
Natera presents a compelling growth story with accelerating revenue, a leadership position in MRD testing, and a recent GAAP profit milestone. However, the stock trades at an extreme premium (PS 13.58x vs. industry 2.5x) and profitability remains inconsistent, with Q1 2026 returning to a loss. The bull case is supported by strong analyst sentiment and operational improvements, while the bear case centers on valuation risk and competitive threats. The single most important tension is whether Natera can sustain its high growth rate and achieve consistent profitability to justify its premium valuation; if growth decelerates or margins fail to expand, the stock could face significant de-rating.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue grew 38.8% YoY to $696.6M, up from 33.4% YoY growth in Q4 2025, demonstrating accelerating demand for Natera's diagnostic products, particularly Signatera.
- GAAP Profitability Achieved: Q4 2025 marked the first GAAP profitable quarter with net income of $47.3M and EPS of $0.35, a major milestone that validates the path to sustained profitability and supports the premium valuation.
- Strong Analyst Consensus: With 21 analysts, the consensus rating is Strong Buy (mean 1.5) and the average target price of $336.74 is 1.4% above the current price, indicating broad optimism about the company's growth prospects.
- Leadership in MRD Testing: Signatera is a leading molecular residual disease test with expanding clinical evidence and reimbursement coverage, positioning Natera to capture a significant share of the rapidly growing liquid biopsy market.
Bearish
- Extreme Valuation Premium: The PS ratio of 13.58x is over 5x the industry average of 2.5x, and the PEG ratio of 230.6x implies the market is pricing in decades of hyper-growth, leaving little room for error.
- Negative Profitability Persists: Despite the Q4 2025 profit, Q1 2026 returned to a net loss of $85.1M (EPS -$0.60), showing that profitability is not yet consistent and may be volatile as the company invests heavily in growth.
- High Beta and Volatility: With a beta of 1.514, the stock is 51% more volatile than the market, and the recent max drawdown of -28.2% highlights the risk of significant short-term losses even in an uptrend.
- Analyst Target Range Wide: The low analyst target of $280 is 15.7% below the current price, indicating that even some analysts see significant downside risk, and the wide spread (34%) reflects uncertainty about future performance.
NTRA Technical Analysis
Natera's stock is in a powerful uptrend, with a 1-year price change of +105.02% and a 6-month change of +56.53%. The current price of $332.03 is near the top of its 52-week range, sitting at 99.5% of the high of $333.56, indicating strong momentum and bullish sentiment. This positioning near the highs suggests the stock is being driven by positive fundamentals and investor enthusiasm, though it also raises the risk of short-term overextension.
Beta
1.51
1.51x market volatility
Max Drawdown
-28.2%
Largest decline past year
52-Week Range
$157-$334
Price range past year
Annual Return
+105.0%
Cumulative gain past year
| Period | NTRA Return | S&P 500 |
|---|---|---|
| 1m | +25.7% | +3.6% |
| 3m | +63.4% | +2.7% |
| 6m | +56.5% | +11.4% |
| 1y | +105.0% | +18.7% |
| ytd | +45.1% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NTRA Fundamental Analysis
Natera's revenue growth is accelerating, with Q1 2026 revenue of $696.6 million, up 38.8% year-over-year, and a sequential increase from $665.5 million in Q4 2025. The company's oncology segment, which includes Signatera, is a key growth driver, with product revenue of $693.9 million in the latest quarter. This robust growth trajectory is a positive signal for the investment case, as it demonstrates strong market demand for the company's diagnostic products.
Quarterly Revenue
$696644000.0B
2026-03
Revenue YoY Growth
+38.8%
YoY Comparison
Gross Margin
64.8%
Latest Quarter
Free Cash Flow
$92010000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NTRA Overvalued?
Given that Natera's trailing twelve-month net income is negative (EPS of -$0.0066), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 13.58x, which is significantly higher than the industry average of 2.5x, indicating a premium valuation. This premium is justified by the company's high growth rate (38.8% YoY) and its leadership in the MRD testing market, but it also implies that the market has high expectations for future profitability.
PE
-150.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-138.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are elevated due to the company's negative net income and reliance on external funding. The TTM net margin is -9.0%, and Q1 2026 net loss was $85.1M, though the company has a strong current ratio of 3.39 and low debt-to-equity of 0.125, providing liquidity to fund operations. However, the negative free cash flow (TTM FCF of $92M is positive, but that is an anomaly; actually FCF was positive, but the company still relies on equity issuance to fund growth, as seen in the increasing share count from 124.7M in Q4 2024 to 141.5M in Q1 2026. The high PS ratio of 13.58x implies that any miss in growth expectations could lead to a sharp de-rating, and the company's history of losses means there is no earnings cushion to absorb shocks.
FAQ
The key risks are: 1) Valuation risk, as the PS ratio of 13.58x is extremely high and could compress if growth slows; 2) Financial risk, as the company is not consistently profitable (Q1 2026 net loss of $85.1M); 3) Competitive risk, from companies like Guardant Health and Exact Sciences in the MRD space; and 4) Macro risk, as the high beta of 1.514 makes the stock sensitive to market downturns. The most severe risk is a combination of growth deceleration and market de-rating, which could lead to a -15% or more decline.
The 12-month forecast is bullish, with a base case target of $336.74 (1.4% upside), a bull case target of $375 (12.9% upside), and a bear case target of $280 (-15.7% downside). The probabilities are 50% base, 30% bull, and 20% bear. The most likely scenario is that Natera continues to grow revenue at 30-40% and gradually improves profitability, leading to a modest upside. However, the stock's high valuation means that the actual outcome will depend heavily on the company's ability to meet or exceed growth expectations.
NTRA is significantly overvalued relative to its industry peers, with a PS ratio of 13.58x versus the industry average of 2.5x. The PEG ratio of 230.6x is extremely high, indicating that the market is pricing in decades of hyper-growth. However, the company's revenue growth of 38.8% YoY and recent GAAP profitability in Q4 2025 justify a premium, but the current valuation leaves little room for error. The market is expecting sustained high growth and eventual profitability, and any disappointment could lead to a sharp de-rating.
NTRA is a good buy for investors with a high risk tolerance and a long-term horizon, given its strong growth trajectory and leadership in MRD testing. The analyst consensus is Strong Buy, and the average target price of $336.74 is slightly above the current price, but the stock trades at a premium valuation with a PS ratio of 13.58x. The biggest risk is valuation compression if growth decelerates, so it is not suitable for conservative investors. For those who believe in the long-term potential of liquid biopsy, NTRA offers significant upside, but they should be prepared for volatility.
NTRA is more suitable for long-term investment, given its high growth potential and the emerging nature of the MRD market. The stock has a beta of 1.514, indicating high volatility, which makes it risky for short-term trading. The company is still in a growth phase with inconsistent profitability, so long-term investors should be prepared for fluctuations. A minimum holding period of 3-5 years is recommended to allow the company to realize its potential and for the market to reward its growth. Short-term traders may find opportunities, but the risk of sharp drawdowns is significant.